A detailed history of First Trust Advisors LP transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 110,923 shares of AGIO stock, worth $3.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,923
Previous 130,411 14.94%
Holding current value
$3.79 Million
Previous $5.62 Million 12.36%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$41.19 - $49.72 $802,710 - $968,943
-19,488 Reduced 14.94%
110,923 $4.93 Million
Q2 2024

Aug 13, 2024

BUY
$27.55 - $48.83 $3.59 Million - $6.37 Million
130,411 New
130,411 $5.62 Million
Q4 2023

Feb 13, 2024

BUY
$19.97 - $24.53 $868,215 - $1.07 Million
43,476 Added 2.45%
1,818,643 $40.5 Million
Q3 2023

Nov 13, 2023

SELL
$24.36 - $28.18 $9.39 Million - $10.9 Million
-385,409 Reduced 17.84%
1,775,167 $43.9 Million
Q2 2023

Aug 14, 2023

BUY
$21.38 - $29.19 $6.9 Million - $9.43 Million
322,959 Added 17.57%
2,160,576 $61.2 Million
Q1 2023

May 15, 2023

BUY
$21.74 - $30.93 $4.5 Million - $6.4 Million
206,791 Added 12.68%
1,837,617 $42.2 Million
Q4 2022

Feb 09, 2023

SELL
$24.81 - $31.52 $8.82 Million - $11.2 Million
-355,339 Reduced 17.89%
1,630,826 $45.8 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $5 Million - $8.76 Million
256,511 Added 14.83%
1,986,165 $56.2 Million
Q2 2022

Aug 12, 2022

BUY
$17.06 - $31.42 $1.98 Million - $3.65 Million
116,225 Added 7.2%
1,729,654 $38.3 Million
Q1 2022

May 13, 2022

BUY
$26.68 - $34.81 $9.2 Million - $12 Million
344,959 Added 27.19%
1,613,429 $47 Million
Q4 2021

Feb 08, 2022

BUY
$29.58 - $49.78 $4.96 Million - $8.35 Million
167,687 Added 15.23%
1,268,470 $41.7 Million
Q3 2021

Nov 15, 2021

SELL
$41.92 - $58.18 $16.6 Million - $23 Million
-395,313 Reduced 26.42%
1,100,783 $50.8 Million
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $3.3 Million - $3.88 Million
-63,405 Reduced 4.07%
1,496,096 $82.5 Million
Q1 2021

May 14, 2021

SELL
$44.23 - $57.5 $11.6 Million - $15.1 Million
-262,880 Reduced 14.43%
1,559,501 $80.5 Million
Q4 2020

Feb 02, 2021

BUY
$33.21 - $46.54 $559,223 - $783,687
16,839 Added 0.93%
1,822,381 $79 Million
Q3 2020

Nov 05, 2020

BUY
$33.87 - $55.93 $7.29 Million - $12 Million
215,151 Added 13.53%
1,805,542 $63.2 Million
Q2 2020

Jul 22, 2020

BUY
$34.45 - $53.48 $11.6 Million - $18 Million
337,397 Added 26.93%
1,590,391 $85.1 Million
Q1 2020

May 06, 2020

SELL
$31.52 - $53.81 $8.85 Million - $15.1 Million
-280,755 Reduced 18.31%
1,252,994 $44.5 Million
Q4 2019

Feb 03, 2020

BUY
$30.08 - $50.59 $7.18 Million - $12.1 Million
238,728 Added 18.43%
1,533,749 $73.2 Million
Q3 2019

Nov 04, 2019

SELL
$32.4 - $49.58 $16 Million - $24.5 Million
-495,105 Reduced 27.66%
1,295,021 $42 Million
Q2 2019

Jul 30, 2019

BUY
$46.17 - $68.1 $737,242 - $1.09 Million
15,968 Added 0.9%
1,790,126 $89.3 Million
Q1 2019

May 09, 2019

BUY
$45.92 - $67.67 $19.5 Million - $28.7 Million
423,931 Added 31.4%
1,774,158 $120 Million
Q4 2018

Feb 07, 2019

BUY
$42.73 - $76.53 $8.04 Million - $14.4 Million
188,217 Added 16.2%
1,350,227 $62.3 Million
Q3 2018

Oct 25, 2018

BUY
$71.67 - $91.95 $30.8 Million - $39.6 Million
430,216 Added 58.79%
1,162,010 $89.6 Million
Q2 2018

Aug 02, 2018

BUY
$73.22 - $99.55 $4.1 Million - $5.58 Million
56,038 Added 8.29%
731,794 $61.6 Million
Q1 2018

Apr 23, 2018

SELL
$59.83 - $86.53 $8.25 Million - $11.9 Million
-137,891 Reduced 16.95%
675,756 $55.3 Million
Q4 2017

Feb 08, 2018

BUY
$52.12 - $72.33 $8.83 Million - $12.2 Million
169,331 Added 26.28%
813,647 $46.5 Million
Q3 2017

Oct 24, 2017

BUY
$54.89 - $67.12 $35.4 Million - $43.2 Million
644,316
644,316 $43 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.87B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.